Reliability of receptor assessment on core needle biopsy in breast cancer patients

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 987-994

  Seferina, S C ^a   Nap, M ^b   Van Den Berkmortel, F ^b   Wals, J ^b   Voogd, A C ^a   Tjan Heijnen, V C G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

Author keywords

Breast cancer; Core needle biopsy; Estrogen receptor; HER2; Progesterone receptor; Resection specimen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PRIORITY JOURNAL; ADJUVANT THERAPY; BREAST TUMOR; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; LARGE CORE NEEDLE BIOPSY; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY;

BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877155225     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0635-5     Document Type: Article

References (39)

1. Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005;23(22):5148-54.
2. Richter-Ehrenstein C, Muller S, Noske A, Schneider A. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients. Int J Surg Pathol. 2009;17(4):323-6.
3. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-92.
4. Leers MP, Hoop JG, van Beers M, van Rodijnen N, Pannebakker M, Nap M. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas. Cytometry. 2005;64(1):43-52.
5. Leers MP, Schoffelen RH, Hoop JG, Theunissen PH, Oosterhuis JW, vd Bijl H, et al. Multiparameter flow cytometry as a tool for the detection of micrometastatic tumour cells in the sentinel lymph node procedure of patients with breast cancer. J Clin Pathol. 2002;55(5):359-66.
6. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996;74(9):1445-51.
7. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-45.
8. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast (Edinburgh, Scotland). 2006;15(2):167-72.
9. Usami S, Moriya T, Amari M, Suzuki A, Ishida T, Sasano H, et al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol. 2007;37(4):250-5.
10. Cahill RA, Walsh D, Landers RJ, Watson RG. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann Surg Oncol. 2006;13(1):45-51.
11. Badoual C, Maruani A, Ghorra C, Lebas P, Avigdor S, Michenet P. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies - correlation with subsequent surgical excisions. Breast (Edinburgh, Scotland). 2005;14(1):22-7.
12. Al Sarakbi W, Salhab M, Thomas V, Mokbel K. Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer? Int Semin Surg Oncol. 2005 Aug 22;2:15.
13. Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 2009;20(12):1948-52.
14. Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Roka S, et al. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr. 2004;116(1-2):26-31.
15. Cavaliere A, Sidoni A, Scheibel M, Bellezza G, Brachelente G, Vitali R, et al. Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett. 2005;218(1):117-21.
16. Mueller-Holzner E, Fink V, Frede T, Marth C. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast cancer research and treatment. 2001;69(1):13-9.
17. Sutela A, Vanninen R, Sudah M, Berg M, Kiviniemi V, Rummukainen J, et al. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer. Acta Oncologica (Stockholm, Sweden). 2008;47(1):38-46.
18. Apple SK, Lowe AC, Rao PN, Shintaku IP, Moatamed NA. Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol. 2009;22(9):1151-9.
19. Ough M, Velasco J, Hieken TJ. A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. Am J Surg. 2010;201(5):692-4.
20. Park SY, Kim KS, Lee TG, Park SS, Kim SM, Han W, et al. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. Am J Surg. 2009;197(2):266-9.
21. Lebeau A, Turzynski A, Braun S, Behrhof W, Fleige B, Schmitt WD, et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol. 2010;28(20):3264-70.
22. van der Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2010;37(6):422-30.
23. Zidan A, Christie Brown JS, Peston D, Shousha S. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol. 1997;50(1):27-9.
24. Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol. 2008;21(4):363-8.
25. Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24(7):1016-9.
26. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53(2):125-30.
27. Cyr A, Gillanders WE, Aft RL, Eberlein TJ, Margenthaler JA. Breast cancer in elderly women (>/= 80 years): variation in standard of care? J Surg Oncol. 2011;103(3):201-6.
28. Thakkar JP, Mehta DG. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist. 2011;16(3):276-85.
29. Lacroix M, Toillon RA, Leclercq G. Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocrine-related cancer. 2004;11(3):497-522.
30. Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol. 2007;25(28):4423-30.
31. Pathmanathan N, Provan PJ, Mahajan H, Hall G, Byth K, Bilous AM, et al. Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing. Breast (Edinburgh, Scotland). 2012;21(6):724-9.
32. Ozdemir A, Voyvoda NK, Gultekin S, Tuncbilek I, Dursun A, Yamac D. Can core biopsy be used instead of surgical biopsy in the diagnosis and prognostic factor analysis of breast carcinoma? Clinical breast cancer. 2007;7(10):791-5.
33. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. Aug 27;378(9793):771-84.
34. von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. Journal of the National Cancer Institute. 2008;100(8):542-51.
35. Liberman L, Dershaw DD, Rosen PP, Abramson AF, Deutch BM, Hann LE. Stereotaxic 14-gauge breast biopsy: how many core biopsy specimens are needed? Radiology. 1994;192(3):793-5.
36. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351-7.
37. Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol. 2008;19(3):487-95.
38. Allred DC. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist. 2008;13(11):1134-6.
39. Rossing HH, Talman ML, Laenkholm AV, Wielenga VT. Implementation of TMA and digitalization in routine diagnostics of breast pathology. APMIS. 2012;120(4):341-7.